ArticleCureus2025
Tranexamic Acid Use in Neck of Femur Fractures: Impact on Blood Loss and Clinical Outcomes at a UK Teaching Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Patients with neck of femur (NOF) fractures experience high morbidity and transfusion rates. Tranexamic acid (TXA) routinely reduces perioperative blood loss in elective lower limb arthroplasties; however, its use in fragility fracture management remains variable, and there is no nationally agreed guideline for its use in hip fracture surgery. This study aims to evaluate the impact of TXA administration on transfusion rates, postoperative hemoglobin drop, in-hospital complications, and 30-day mortality in patients with NOF fractures at a UK-based teaching hospital. Methods A retrospective audit at a university trauma unit evaluated TXA use in patients with NOF fractures from July to December 2024. Of 184 cases identified, 26 were excluded (preoperative death, transfer, or non-NOF fractures), leaving 158 patients for analysis. Patients were grouped based on TXA administration. The primary outcome was the need for blood transfusion intraoperatively or within one week postoperatively. Secondary outcomes included postoperative hemoglobin drop, thromboembolic events, and 30-day mortality. Results Among 158 patients, 144 (91.1%) received TXA. Transfusion rates were significantly lower in the TXA group (22.2%) compared with non-TXA patients (50.0%) (χ² = 5.30, p = 0.021). Mean postoperative hemoglobin drop was smaller with TXA (17.1 ± 13.4 g/L vs. 22.8 ± 17.2 g/L; Z = -2.34, p = 0.019). Binary logistic regression identified TXA as an independent protective factor (OR: 0.164, 95% CI: 0.042-0.648, p = 0.011), while female sex, American Society of Anesthesiologists (ASA) grade III-IV, and extracapsular fractures were independent predictors of transfusion. There was no significant difference in thromboembolic events (3.5% vs. 7.1%, p = 0.432) or 30-day mortality (6.3% vs. 21.4%, p = 0.095), suggesting TXA did not increase these risks. Conclusion In this cohort, perioperative TXA use in operative NOF fracture management significantly reduced transfusion rates and hemoglobin drop without a significant effect on 30-day mortality and no effect on thromboembolic events. These findings support routine TXA use as a low-risk, cost-effective adjunct in the surgical management of patients with NOF fractures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.